Masaki Takagi1, Keisuke Nagasaki2, Ikuma Fujiwara2, Tomohiro Ishii2, Naoko Amano2, Yumi Asakura2, Koji Muroya2, Yukihiro Hasegawa2, Masanori Adachi2, Tomonobu Hasegawa3. 1. Department of Endocrinology and MetabolismTokyo Metropolitan Children's Medical Center, Tokyo, JapanDepartment of PediatricsSchool of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, JapanDivision of PediatricsDepartment of Homeostatic Regulation and Development, Graduate School of Medicine and Dental Sciences, Niigata University, Niigata, JapanDepartment of PediatricsSchool of Medicine, Tohoku University, Miyagi, JapanDepartment of Endocrinology and MetabolismKanagawa Children's Medical Center, Yokohama, Japan Department of Endocrinology and MetabolismTokyo Metropolitan Children's Medical Center, Tokyo, JapanDepartment of PediatricsSchool of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, JapanDivision of PediatricsDepartment of Homeostatic Regulation and Development, Graduate School of Medicine and Dental Sciences, Niigata University, Niigata, JapanDepartment of PediatricsSchool of Medicine, Tohoku University, Miyagi, JapanDepartment of Endocrinology and MetabolismKanagawa Children's Medical Center, Yokohama, Japan. 2. Department of Endocrinology and MetabolismTokyo Metropolitan Children's Medical Center, Tokyo, JapanDepartment of PediatricsSchool of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, JapanDivision of PediatricsDepartment of Homeostatic Regulation and Development, Graduate School of Medicine and Dental Sciences, Niigata University, Niigata, JapanDepartment of PediatricsSchool of Medicine, Tohoku University, Miyagi, JapanDepartment of Endocrinology and MetabolismKanagawa Children's Medical Center, Yokohama, Japan. 3. Department of Endocrinology and MetabolismTokyo Metropolitan Children's Medical Center, Tokyo, JapanDepartment of PediatricsSchool of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, JapanDivision of PediatricsDepartment of Homeostatic Regulation and Development, Graduate School of Medicine and Dental Sciences, Niigata University, Niigata, JapanDepartment of PediatricsSchool of Medicine, Tohoku University, Miyagi, JapanDepartment of Endocrinology and MetabolismKanagawa Children's Medical Center, Yokohama, Japan thaseg@a6.keio.jp.
Abstract
BACKGROUND: The prevalence of congenital hypopituitarism (CH) attributable to known transcription factor mutations appears to be rare and other causative genes for CH remain to be identified. Due to the sporadic occurrence of CH, de novo chromosomal rearrangements could be one of the molecular mechanisms participating in its etiology, especially in syndromic cases. OBJECTIVE: To identify the role of copy number variations (CNVs) in the etiology of CH and to identify novel genes implicated in CH. SUBJECTS AND METHODS: We enrolled 88 (syndromic: 30; non-syndromic: 58) Japanese CH patients. We performed an array comparative genomic hybridization screening in the 30 syndromic CH patients. For all the 88 patients, we analyzed PAX6 by PCR-based sequencing. RESULTS: We identified one heterozygous 310-kb deletion of the PAX6 enhancer region in one patient showing isolated GH deficiency (IGHD), cleft palate, and optic disc cupping. We also identified one heterozygous 6.5-Mb deletion encompassing OTX2 in a patient with bilateral anophthalmia and multiple pituitary hormone deficiency. We identified a novel PAX6 mutation, namely p.N116S in one non-syndromic CH patient showing IGHD. The p.N116S PAX6 was associated with an impairment of the transactivation capacities of the PAX6-binding elements. CONCLUSIONS: This study showed that heterozygous PAX6 mutations are associated with CH patients. PAX6 mutations may be associated with diverse clinical features ranging from severely impaired ocular and pituitary development to apparently normal phenotype. Overall, this study identified causative CNVs with a possible role in the etiology of CH in <10% of syndromic CH patients.
BACKGROUND: The prevalence of congenital hypopituitarism (CH) attributable to known transcription factor mutations appears to be rare and other causative genes for CH remain to be identified. Due to the sporadic occurrence of CH, de novo chromosomal rearrangements could be one of the molecular mechanisms participating in its etiology, especially in syndromic cases. OBJECTIVE: To identify the role of copy number variations (CNVs) in the etiology of CH and to identify novel genes implicated in CH. SUBJECTS AND METHODS: We enrolled 88 (syndromic: 30; non-syndromic: 58) Japanese CH patients. We performed an array comparative genomic hybridization screening in the 30 syndromic CHpatients. For all the 88 patients, we analyzed PAX6 by PCR-based sequencing. RESULTS: We identified one heterozygous 310-kb deletion of the PAX6 enhancer region in one patient showing isolated GH deficiency (IGHD), cleft palate, and optic disc cupping. We also identified one heterozygous 6.5-Mb deletion encompassing OTX2 in a patient with bilateral anophthalmia and multiple pituitary hormone deficiency. We identified a novel PAX6 mutation, namely p.N116S in one non-syndromic CHpatient showing IGHD. The p.N116SPAX6 was associated with an impairment of the transactivation capacities of the PAX6-binding elements. CONCLUSIONS: This study showed that heterozygous PAX6 mutations are associated with CH patients. PAX6 mutations may be associated with diverse clinical features ranging from severely impaired ocular and pituitary development to apparently normal phenotype. Overall, this study identified causative CNVs with a possible role in the etiology of CH in <10% of syndromic CHpatients.
Authors: Qing Fang; Akima S George; Michelle L Brinkmeier; Amanda H Mortensen; Peter Gergics; Leonard Y M Cheung; Alexandre Z Daly; Adnan Ajmal; María Ines Pérez Millán; A Bilge Ozel; Jacob O Kitzman; Ryan E Mills; Jun Z Li; Sally A Camper Journal: Endocr Rev Date: 2016-11-09 Impact factor: 19.871